Merck & Co., Inc. (MRK)
115.39
-4.89
(-4.07%)
USD |
NYSE |
Mar 05, 11:15
Merck Cash from Investing (Quarterly) : -11.20B for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -693.00M |
| Gilead Sciences, Inc. | -1.835B |
| Johnson & Johnson | -4.485B |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| Moderna, Inc. | -48.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.857B |
| Cash from Financing (Quarterly) | 4.751B |
| Free Cash Flow | 12.36B |
| Free Cash Flow Per Share (Quarterly) | 0.7331 |
| Free Cash Flow to Equity (Quarterly) | -7.336B |
| Free Cash Flow to Firm (Quarterly) | 2.180B |
| Free Cash Flow Yield | 4.27% |